Ichor’s Auctus Biologics Closes Quick $1.5MM

Posted Posted in Auctus Biologics, Ichor

Auctus Biologcs, Inc., a new portfolio company of Ichor Therapeutics, Inc., announced today the closure of $1.5MM in seed funding. The company will develop RPtag, a hyper-stable antibody mimetic scaffold published earlier this year in the peer-reviewed journal ACS Biochemistry, to take on conventional clinical antibody therapy as an orally bioavailable formulation. New high priority immunosenescence and gastrointestinal targets will also be pursued.

Ichor Portfolio Company, Antoxerene, Closes $10MM Deal with Juvenescence

Posted Posted in Antoxerene, FoxBio, Ichor

Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of a joint venture with Juvenescence Limited. The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence will support the venture with $10 million in equity financing and drug development expertise.

Industry Leader Joins Ichor Therapeutics as Chief Medical Officer

Posted Posted in Antoxerene, Ichor, Lysoclear

Ichor Therapeutics, a pre-clinical contract research organization, recently announced the appointment of Cornelis (Cees) Hendrik Wortel MD, PhD to the position of Chief Medical Officer (CMO). Dr. Wortel brings over 25 years of experience to Ichor, having worked as a senior (bio) pharmaceutical executive for early stage and established companies, both nationally and internationally. Most notably, he has been involved in the development of Remicade® (the first anti-TNF biological drug) and in a very large number of clinical trials, Phase I to IV, bringing innovative first-in-class drugs to market.

Ichor Unveils Orally Bioavailable Antibody-like Scaffold in ACS Biochemistry

Posted Posted in Antoxerene, Ichor, RecombiPure

A landmark biotechnology was published for the first time in the peer-reviewed journal ACS Biochemistry. The article, “RPtag as an orally bioavailable, hyper stable epitope tag and generalizable protein binding scaffold,” describes a foundational technology that could have huge implications in drug discovery, diagnostics, and clinical antibody therapy.

Ichor CEO Delivers Keynote at TriBeta Northeast Conference

Posted Posted in Ichor

The State University of New York at Fredonia hosted the Northeastern District-3 Conference for TriBeta, the Biology Honor Society. Kelsey Moody, CEO at Ichor Therapeutics, delivered the keynote address. In the address, he discussed Ichor’s humble beginnings in a West Syracuse apartment, and encouraging pre-clinical results from the company’s age-related macular degeneration program.